早產診斷檢測套組市場規模、佔有率及成長分析（按測試類型、檢體類型、最終用戶和地區分類）－2026-2033年產業預測

預計到 2024 年，早產診斷檢測套組市場規模將達到 1.6377 億美元，到 2025 年將達到 1.7621 億美元，到 2033 年將達到 3.1662 億美元，預測期（2026-2033 年）的複合年成長率為 7.6%。

早產診斷檢測套組市場正經歷顯著成長，這主要得益於早產發生率的上升以及對早期檢測方法的迫切需求。這些試劑盒利用生物標記分析和臨床指標進行高效的風險評估，而醫護人員和孕婦對早產的意識提升，也推動了這一成長。診斷技術的進步同樣是推動市場發展的重要因素，其中擁有先進醫療體系的北美和歐洲佔據了相當大的市場佔有率。同時，亞太地區也展現出巨大的發展潛力，這主要得益於醫療投入的增加和公眾意識的提升。一個值得關注的趨勢是，就地檢驗）正日益普及，它能夠實現即時評估和及時醫療干預，這對於醫療資源匱乏的地區尤其重要。

早產兒診斷檢測套組市場促進因素

早產率（指妊娠不足37週分娩）的上升已成為全球公共衛生面臨的重大挑戰。這一趨勢促使人們迫切需要準確可靠的診斷檢測套組來識別和預測早產。對改善孕產婦和新生兒健康的重視，以及醫療機構和政策制定者為降低早產率所做的努力，確保了對這些重要診斷工具的持續需求。隨著人們對早產影響的認知不斷提高，預計這些檢測套組的市場將進一步擴大。

早產診斷檢測套組市場的限制

由於醫療診斷行業受到嚴格監管，以確保患者安全和產品有效性，早產兒診斷檢測套組市場面臨嚴峻挑戰。開發和推出新的診斷檢測套組，特別是那些專注於懷孕和新生兒健康的試劑盒，需要經過大量的測試和核准流程。這些監管障礙可能會阻礙創新檢測套組的及時上市，最終影響其市場供應以及醫療機構和患者的接受度。

早產診斷檢測套組市場趨勢

受診斷技術進步的推動，早產診斷檢測套組市場正經歷顯著的發展趨勢。創新技術不斷湧現，創造出更精準可靠的檢測方案，使醫療專業人員能夠更精確地預測早產風險。這一市場發展趨勢涵蓋了多種生物標記、基因檢測、蛋白質組學以及其他前沿調查方法的整合，這些方法共同提高了診斷測試的敏感度和特異性。因此，人們越來越關注個人化孕產婦照護和早期療育策略，並將這些檢測套組視為改善懷孕結果和降低早產率的關鍵工具。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境
• 專利分析

全球早產診斷檢測套組市場規模（按檢測類型和複合年成長率分類）（2026-2033 年）

• 胎兒纖維蛋白原 (fFN)檢測套組
• 胎盤α-微球蛋白-1 (PAMG-1)檢測套組
• 類胰島素生長因子結合蛋白質-1 (IGFBP-1)檢測套組

全球早產診斷檢測套組市場規模（按檢體類型和複合年成長率分類）（2026-2033 年）

• 血液樣本
• 尿液樣本
• 陰道分泌物樣本

全球早產診斷檢測套組市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診斷檢查室
• 專科診所

全球早產診斷檢測套組市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Roche Diagnostics（Switzerland）
• Abbott Laboratories（USA）
• Siemens Healthineers（Germany）
• Thermo Fisher Scientific（USA）
• BD（Becton, Dickinson and Company）（USA）
• PerkinElmer（USA）
• bioMerieux（France）
• Hologic, Inc.（USA）
• Qiagen（Netherlands）
• Danaher Corporation（USA）
• Cepheid（USA）
• Illumina, Inc.（USA）
• Sysmex Corporation（Japan）
• Agilent Technologies（USA）
• Bio-Rad Laboratories（USA）
• GenMark Diagnostics（USA）
• Luminex Corporation（USA）
• Randox Laboratories（UK）
• NanoString Technologies（USA）
• Myriad Genetics（USA）

結論與建議

Preterm Birth Diagnostic Test Kits Market size was valued at USD 163.77 Million in 2024 and is poised to grow from USD 176.21 Million in 2025 to USD 316.62 Million by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The market for Preterm Birth Diagnostic Test Kits is experiencing significant growth, propelled by the increasing incidence of preterm births and the urgent need for early detection methods. These kits utilize biomarker analysis and clinical indicators for efficient risk assessment, backed by heightened awareness among healthcare professionals and expectant mothers. Advancements in diagnostic technology further drive this market, with North America and Europe commanding substantial shares due to their advanced healthcare systems. Meanwhile, the Asia-Pacific region showcases promising potential, spurred by rising healthcare investments and awareness levels. A notable trend is the shift toward point-of-care testing, which allows for immediate assessments and timely healthcare interventions, particularly beneficial in areas with limited access to sophisticated medical facilities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Preterm Birth Diagnostic Test Kits market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Preterm Birth Diagnostic Test Kits Market Segments Analysis

Global Preterm Birth Diagnostic Test Kits Market is segmented by Test Type, Sample Type, End User and region. Based on Test Type, the market is segmented into Fetal Fibronectin (fFN) Test Kits, Placental Alpha Microglobulin-1 (PAMG-1) Test Kits and Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Test Kits. Based on Sample Type, the market is segmented into Blood Sample, Urine Sample and Vaginal Discharge Sample. Based on End User, the market is segmented into Hospitals, Diagnostic Laboratories and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Preterm Birth Diagnostic Test Kits Market

The rising prevalence of preterm births, characterized by delivery before 37 weeks of pregnancy, presents a critical public health challenge worldwide. This growing trend fuels the need for precise and dependable diagnostic test kits aimed at identifying and forecasting preterm labor. The focus on enhancing maternal and neonatal health outcomes, along with the efforts of healthcare providers and policymakers to mitigate preterm birth rates, ensures a sustained demand for these essential diagnostic tools. As awareness of the implications of preterm birth continues to grow, the market for these test kits is expected to expand further.

Restraints in the Preterm Birth Diagnostic Test Kits Market

The preterm birth diagnostic test kits market faces significant challenges due to the stringent regulations governing the medical diagnostic industry, which are in place to safeguard patient safety and ensure product effectiveness. The process of developing and bringing new diagnostic test kits to market, particularly those focused on pregnancy and neonatal health, involves extensive testing and approval requirements. These regulatory obstacles can hinder the timely launch of innovative test kits, ultimately affecting their market availability and the rate at which they are adopted by healthcare providers and patients alike.

Market Trends of the Preterm Birth Diagnostic Test Kits Market

The preterm birth diagnostic test kits market is experiencing a significant trend driven by advancements in diagnostic technologies. Innovations are leading to the creation of more accurate and reliable testing options that empower healthcare professionals to predict preterm birth risk with enhanced precision. This market evolution encompasses the integration of diverse biomarkers, genetic testing, and proteomics, alongside other cutting-edge methodologies, which collectively improve the sensitivity and specificity of the diagnostic tests. As a result, the focus on personalized maternal care and early intervention strategies is intensifying, positioning these test kits as crucial tools in improving pregnancy outcomes and reducing preterm birth rates.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Preterm Birth Diagnostic Test Kits Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Fetal Fibronectin (fFN) Test Kits
• Placental Alpha Microglobulin-1 (PAMG-1) Test Kits
• Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Test Kits

Global Preterm Birth Diagnostic Test Kits Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood Sample
• Urine Sample
• Vaginal Discharge Sample

Global Preterm Birth Diagnostic Test Kits Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Specialty Clinics

Global Preterm Birth Diagnostic Test Kits Market Size & CAGR (2026-2033)

• North America (Test Type, Sample Type, End User)
  • US
  • Canada
• Europe (Test Type, Sample Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Sample Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Sample Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Sample Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BD (Becton, Dickinson and Company) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenMark Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luminex Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations